Skip to main content

Market Overview

Amarin's Vascepa Associated With Stroke Reduction


Amarin Corporation plc (NASDAQ: AMRN) has announced new prespecified and post hoc analyses from the REDUCE-IT study, evaluating Vascepa (icosapent ethyl). Data were presented at International Stroke Conference 2021.

  • The REDUCE-IT STROKE analyses examined stroke rates across the enrolled patient population (n=8179).
  • The study showed 28% and 32% significant reductions in first and total strokes, demonstrated with Vascepa compared to placebo.
  • Reductions in first and total ischemic strokes each by 36%, without increasing hemorrhagic stroke, in statin-treated patients with elevated cardiovascular risk.
  • Consistent reductions in overall stroke and ischemic stroke were observed across multiple subgroups.
  • Price Action: AMRN shares are trading 3.4% higher at $6.70 in market trading hours on the last check Wednesday.

Related Articles (AMRN)

View Comments and Join the Discussion!

Posted-In: StrokeBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at